Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 3 Study Of Docetaxel In Combination With Sunitinib Versus Docetaxel In The First-Line Treatment Of Advanced Breast Cancer Patients

NCT00393939 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00393939
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00393939 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 3 Study Of Docetaxel In Combination With Sunitinib Versus Docetaxel In The First-Line Treatment Of Advanced Breast Cancer Patients
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2007
Completion date
July 31, 2011
Enrollment
594 (actual)
Sites
144

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms